ArticleBioinformatics (Oxford, England)2025
High-dimensional biomarker identification for interpretable disease prediction via machine learning models.
Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Integrated Transcriptomic Analysis and Machine Learning Identify THY1 as a Key Regulator of Cancer-Associated Fibroblast Infiltration, Promoting Malignant Progression and Immune Escape in Gastric Cancer.Journal of gastroenterology and hepatology · 2026Article
- scDiagnostics: systematic assessment of cell type annotation in single-cell transcriptomics data.Briefings in bioinformatics · 2026Article
- Artificial intelligence in plant salt stress research: from predictive models to multi-omics integration.Journal of experimental botany · 2026Review
- Data-intensive immune network modelling for One Health.Briefings in bioinformatics · 2026Review
- Prediction of atelectasis inFrontiers in pediatrics · 2026Article
- Plasma Proteomic Profile of Dietary Potassium and Incident CKD.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- On Selecting Robust Approaches for Learning Predictive Biomarkers in Metabolomics Data Sets.Analytical chemistry · 2025Article
- Cross-species validation of a 6-miRNA blood signature for Parkinson's disease: from MPTP mice to human PBMC and serum exosomes.Frontiers in neurology · 2025Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
motivationOmics features, often measured by high-throughput technologies, combined with clinical features, significantly impact the understanding of many complex human diseases. Integrating key omics biomarkers with clinical risk factors is essential for elucidating disease mechanisms, advancing early diagnosis, and enhancing precision medicine. However, the high dimensionality and intricate associations between disease outcomes and omics profiles present substantial analytical challenges.
resultsWe propose a high-dimensional feature importance test (HiFIT) framework to address these challenges. Specifically, we develop an ensemble data-driven biomarker identification tool, Hybrid Feature Screening (HFS), to construct a candidate feature set for downstream machine learning models. The pre-screened candidate features from HFS are further refined using a computationally efficient permutation-based feature importance test employing machine learning methods to flexibly model the potential complex associations between disease outcomes and molecular biomarkers. Through extensive numerical simulation studies and practical applications to microbiome-associated weight changes following bariatric surgery, as well as the examination of gene-expression-associated kidney pan-cancer survival data, we demonstrate HiFIT's superior performance in both outcome prediction and feature importance identification. AVAILABILITY AND IMPLEMENTATION: An R package implementing the HiFIT algorithm is available on GitHub (https://github.com/BZou-lab/HiFIT).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.